IFNAR1 and IFNAR2 play distinct roles in initiating type I interferon-induced JAK-STAT signaling and activating STATs.


Journal

Science signaling
ISSN: 1937-9145
Titre abrégé: Sci Signal
Pays: United States
ID NLM: 101465400

Informations de publication

Date de publication:
23 Nov 2021
Historique:
entrez: 23 11 2021
pubmed: 24 11 2021
medline: 18 1 2022
Statut: ppublish

Résumé

Type I interferons bind to cell surface receptors composed of the subunits IFNAR1 and IFNAR2, the intracellular domains (ICDs) of which are associated with the kinases TYK2 and JAK1, respectively. Ligand binding results in the cross-phosphorylation of TYK2 and JAK1, which then phosphorylate tyrosine residues in the ICDs of the receptor subunits and members of the STAT family of transcription factors. The phosphorylated STATs migrate to the nucleus and drive transcription. We analyzed receptor mutants in knockout cells to study the functional importance of various regions of the receptor ICDs. For IFNAR1, only the TYK2 binding site in the ICD was required for signaling. In contrast, successive truncations of the ICD of IFNAR2 proportionally decreased constitutive STAT binding, STAT phosphorylation, and target gene activation. These findings fit a model in which nonsuccessive stretches along the ICD interact with STATs. Tyrosine residues in the IFNAR1 ICD were not required for signaling, and single tyrosine mutations in the IFNAR2 ICD did not affect signal activation. However, simultaneous mutation of all the tyrosine residues in IFNAR2-ICD reduced STAT phosphorylation, STAT-mediated transcriptional activation, and antiviral activity but not constitutive STAT2 binding. We suggest that tyrosine phosphorylation on IFNAR2-ICD drives the dissociation of phosphorylated STATs, thus maintaining high signaling flux.

Identifiants

pubmed: 34813358
doi: 10.1126/scisignal.abe4627
doi:

Substances chimiques

IFNAR1 protein, human 0
IFNAR2 protein, human 0
Interferon Type I 0
STAT Transcription Factors 0
Receptor, Interferon alpha-beta 156986-95-7
Janus Kinases EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabe4627

Auteurs

Maya Shemesh (M)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.

Sara Lochte (S)

Department of Biology and Center of Cellular Nanoanalytics, University of Osnabrück, 49076 Osnabrück, Germany.

Jacob Piehler (J)

Department of Biology and Center of Cellular Nanoanalytics, University of Osnabrück, 49076 Osnabrück, Germany.

Gideon Schreiber (G)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH